The ability of MIL-38-CD3 BiTE to mediate the activation of T cells in the presence of GPC-1-expressing prostate tumour cells was measured by flow cytometry analysis of the early activation marker CD69 and the late activation marker CD25. Here, GPC1 is linked to prostate neoplasm.